These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29222313)

  • 1. Developing T-cell therapies for lymphoma without receptor engineering.
    Grant M; Bollard CM
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):622-631. PubMed ID: 29222313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing T-cell therapies for lymphoma without receptor engineering.
    Grant M; Bollard CM
    Blood Adv; 2017 Dec; 1(26):2579-2590. PubMed ID: 29296911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular Immunotherapy in Lymphoma: Beyond CART Cells.
    Gaballa MR; Ramos CA
    Curr Treat Options Oncol; 2020 Feb; 21(3):21. PubMed ID: 32048071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.
    Rivière I; Sadelain M
    Mol Ther; 2017 May; 25(5):1117-1124. PubMed ID: 28456379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
    Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
    Li F; Zhang T; Cao L; Zhang Y
    Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.
    Shalabi H; Kraft IL; Wang HW; Yuan CM; Yates B; Delbrook C; Zimbelman JD; Giller R; Stetler-Stevenson M; Jaffe ES; Lee DW; Shern JF; Fry TJ; Shah NN
    Haematologica; 2018 May; 103(5):e215-e218. PubMed ID: 29419431
    [No Abstract]   [Full Text] [Related]  

  • 8. The Promise of Chimeric Antigen Receptor T-Cell Therapy.
    Frey NV; Porter DL
    Oncology (Williston Park); 2016 Oct; 30(10):880-8, 890. PubMed ID: 27744645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!
    Grant ML; Bollard CM
    Blood Rev; 2018 May; 32(3):203-224. PubMed ID: 29198753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DCs in lymphoma--biology and therapeutic aspects.
    Schultze JL; Fiore F; von Bergwelt-Baildon M
    Cytotherapy; 2004; 6(2):138-47. PubMed ID: 15203990
    [No Abstract]   [Full Text] [Related]  

  • 12. Cellular immunotherapy strategies for Ewing sarcoma.
    Rossig C
    Immunotherapy; 2014; 6(5):611-21. PubMed ID: 24896629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
    Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
    Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [T Lymphocytes with Modified Specificity in the Therapy of Malignant Diseases].
    Vdovin AS; Bykova NA; Efimov GA
    Mol Biol (Mosk); 2017; 51(6):1008-1023. PubMed ID: 29271964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
    Kochenderfer JN; Somerville RPT; Lu T; Shi V; Bot A; Rossi J; Xue A; Goff SL; Yang JC; Sherry RM; Klebanoff CA; Kammula US; Sherman M; Perez A; Yuan CM; Feldman T; Friedberg JW; Roschewski MJ; Feldman SA; McIntyre L; Toomey MA; Rosenberg SA
    J Clin Oncol; 2017 Jun; 35(16):1803-1813. PubMed ID: 28291388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
    Liu L; Sun M; Wang Z
    Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune and viral therapies for malignant primary brain tumors.
    Gardeck AM; Sheehan J; Low WC
    Expert Opin Biol Ther; 2017 Apr; 17(4):457-474. PubMed ID: 28274139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T Cell Engineering.
    Pircher M; Schirrmann T; Petrausch U
    Prog Tumor Res; 2015; 42():110-35. PubMed ID: 26383243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma.
    Enblad G; Karlsson H; Loskog AS
    Hum Gene Ther; 2015 Aug; 26(8):498-505. PubMed ID: 26230974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.